Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -102.45% is 884% below its 2-year average of 13.06%, near the low end of its 2-year range (-102.45%–78.00%).
As of the fiscal period ended Tuesday, June 30, 2026. 491.08% below its 12-month average of -17.33%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -102.45%.
RETURN ON EQUITY (ROE)
-102.45%
RETURN ON EQUITY (ROE) AVG TTM
-17.33%
RETURN ON EQUITY (ROE) AVG 3Y
13.06%
RETURN ON EQUITY (ROE) AVG 5Y
13.06%
RETURN ON EQUITY (ROE) AVG 10Y
-89.84%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-491.08%
CURRENT VS 3Y AVG
-884.45%
CURRENT VS 5Y AVG
-884.45%
CURRENT VS 10Y AVG
-14.04%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-38.25%
median of 444 covered companies
CURRENT VS SECTOR MEDIAN
-167.84%
vs the sector median at left
BioStem Technologies, Inc.
Market Cap
$46.79M
Return on Equity (ROE)
-102.45%
TTM Avg
-17.33%
3Y Avg
13.06%
5Y Avg
13.06%
Market Cap
$45.20M
Return on Equity (ROE)
-212.45%
TTM Avg
-170.64%
3Y Avg
-104.70%
5Y Avg
-78.05%
Market Cap
$49.40M
Return on Equity (ROE)
N/A
TTM Avg
-24.59%
3Y Avg
-14.57%
5Y Avg
93.61%
Market Cap
$49.50M
Return on Equity (ROE)
N/A
TTM Avg
-206.96%
3Y Avg
-221.50%
5Y Avg
-349.91%
Market Cap
$49.96M
Return on Equity (ROE)
N/A
TTM Avg
296.81%
3Y Avg
-175.08%
5Y Avg
-1071.79%
Market Cap
$50.25M
Return on Equity (ROE)
-708.48%
TTM Avg
156.13%
3Y Avg
510.26%
5Y Avg
342.91%
Market Cap
$50.51M
Return on Equity (ROE)
N/A
TTM Avg
-382.07%
3Y Avg
-282.25%
5Y Avg
-171.00%
Market Cap
$51.12M
Return on Equity (ROE)
-52.72%
TTM Avg
-32.48%
3Y Avg
-92.81%
5Y Avg
-85.98%
Market Cap
$42.41M
Return on Equity (ROE)
123.04%
TTM Avg
-60.38%
3Y Avg
-75.18%
5Y Avg
-82.51%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | $46.79M | -102.45% | -17.33% | 13.06% | 13.06% |
| Werewolf Therapeutics, Inc. (HOWL)vs › | $45.20M | -212.45% | -170.64% | -104.70% | -78.05% |
| biote Corp. (BTMD)vs › | $49.40M | N/A | -24.59% | -14.57% | 93.61% |
| Celularity Inc. (CELU)vs › | $49.50M | N/A | -206.96% | -221.50% | -349.91% |
| Clene Inc. (CLNN)vs › | $49.96M | N/A | 296.81% | -175.08% | -1071.79% |
| Envoy Medical, Inc. (COCH)vs › | $50.25M | -708.48% | 156.13% | 510.26% | 342.91% |
| Apollomics, Inc. (APLM)vs › | $50.51M | N/A | -382.07% | -282.25% | -171.00% |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $51.12M | -52.72% | -32.48% | -92.81% | -85.98% |
| DarioHealth Corp. (DRIO)vs › | $42.41M | 123.04% | -60.38% | -75.18% | -82.51% |
| eXoZymes, Inc. (EXOZ)vs › | $51.23M | -278.89% | -162.92% | 25.71% | 0.37% |
ROE
-102.4%
ROA
-58.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -102.45% |
| 2026-03-31 | -62.39% |
| 2025-12-31 | -16.81% |
| 2025-09-30 | 40.39% |
| 2025-06-30 | 54.61% |
| 2025-03-31 | 69.68% |
| 2024-12-31 | 78.00% |
| 2024-09-30 | 59.67% |
| 2024-06-30 | 39.59% |
| 2024-03-31 | -29.68% |
| 2018-09-30 | -730.17% |
| 2018-03-31 | -434.03% |
| 2017-12-31 | -470.39% |
| 2017-09-30 | -133.42% |
| 2017-06-30 | -77.07% |
| 2017-03-31 | -89.45% |
| 2016-12-31 | -106.08% |
| 2016-09-30 | -766.25% |
| 2016-06-30 | -347.36% |
| 2016-03-31 | -221.88% |
| 2015-12-31 | -144.75% |
| 2015-09-30 | -369.24% |
| 2015-06-30 | -280.77% |
| 2015-03-31 | -106.83% |
| 2014-03-31 | -430.96% |
| 2013-12-31 | -430.98% |
